What is the role of trifluridine in the novel nucleoside antitumor agent TAS-102?
['["PURPOSE: Trifluridine (TFT) is an antitumor component of a novel nucleoside antitumor agent, TAS-102, which consists of TFT and tipiracil hydrochloride (thymidine phosphorylase inhibitor).", "TAS-102, a combination of trifluorothymidine and the thymidine phosphorylase inhibitor TPI in a 1:0.5 ratio, is a novel oral formulation, which is active in 5FU-resistant models, both in vitro and in xenograft models.", "TAS-102 is a novel oral nucleoside antitumor agent consisting of trifluridine and tipiracil hydrochloride at a molar ratio of 1:0.5. ", "PURPOSE: TAS-102 is an orally administered anticancer agent composed of \\u03b1,\\u03b1,\\u03b1-trifluorothymidine (FTD) and thymidine phosphorylase inhibitor (TPI). ", "Novel DNA synthesis inhibitors for the treatment of gastrointestinal malignancies include a combination of the antimetabolite TAS-102, which consists of trifluorothymidine with a thymidine phosphorylase inhibitor, and a novel micellar formulation of cisplatin NC-6004 that uses a nanotechnology-based drug delivery system. ", "Repeated oral dosing of TAS-102 confers high trifluridine incorporation into DNA and sustained antitumor activity in mouse models.", "TAS-102 is a novel oral nucleoside antitumor agent containing trifluridine (FTD) and tipiracil hydrochloride (TPI)."]']
Trifluridine (TFT) is an antitumor component of TAS-102, which is a novel nucleoside antitumor agent. It is combined with tipiracil hydrochloride (thymidine phosphorylase inhibitor) in TAS-102.
[]